Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879062 | 0.97 | TRPV1 (0.43) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL3878492 | 0.93 | TRPV1 (0.48) | TRPV1GRM5CHRM4MTOR | |
| SCHEMBL3878041 | 0.91 | MALT1 (0.44) | TRPV1MALT1CHRM4 | |
| SCHEMBL3888352 | 0.90 | TRPV1 (0.49) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL3878083 | 0.90 | TRPV1 (0.49) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL13761545 | 0.90 | TRPV1 (0.49) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL3883269 | 0.90 | TRPV1 (0.49) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL3879735 | 0.90 | TRPV1 (0.49) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL13761558 | 0.90 | TRPV1 (0.49) | TRPV1GRM5MALT1CHRM4 | |
| SCHEMBL3878207 | 0.90 | GRM5 (0.41) | TRPV1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | TRPV1 244/4885GRM5 391/4885MALT1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.